Perspectives in the elderly patient: Benefits and limits of bisphosphonates and denosumab

Recent Results in Cancer Research

Volumn 192, Issue , 2012, Pages 171-185

  Santini, Daniele ^a   Fratto, Maria Elisabetta ^a   Aapro, Matti ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CAPECITABINE; CLODRONIC ACID; CREATININE; CYCLOPHOSPHAMIDE; DENOSUMAB; EPIRUBICIN; FLUOROURACIL; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TAXANE DERIVATIVE; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AGE DISTRIBUTION; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CREATININE CLEARANCE; DISEASE CONTROL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; GERIATRIC PATIENT; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MONOTHERAPY; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT ATTITUDE; POPULATION RESEARCH; POSTMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; VERTEBRA FRACTURE;

EID: 84858255680     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-21892-7_8     Document Type: Article

References (44)

1. Barkin RL, Barkin SJ, Barkin DS (2005) Perception, assessment, treatment, and management of pain in the elderly. Clin Geriatr Med 21(3):465-490 (Pubitemid 40720252)
2. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588-1594 (Pubitemid 27444031)
3. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8):1860-1867 (Pubitemid 47557312)
4. Saad F (2008) New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treat Rev 34(2):183-192 (Pubitemid 351384327)
5. Gridelli C (2007) The use of bisphosphonates in elderly cancer patients. Oncologist 12(1):62-71 (Pubitemid 46143503)
6. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini D, Caraglia M, Del Prete S (2008) Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Support Care Cancer 16(2):209-214 Epub 2007 Aug 14
7. Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS (2010) Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther 6(1):31-35
8. Pillai G, Gieschke R, Goggin T, Barrett J, Worth E, Steimer JL (2006) Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmeno-pausal females. Int J Clin Pharmacol Ther 44(12):655-667 (Pubitemid 44896143)
9. Goldschmidt H, Lannert H, Bommer J, Ho AD (2000) Multiple myeloma and renal failure. Nephrol Dial Transplant 15:301-304 (Pubitemid 30116460)
10. Patterson WP, Reams GP (1992) Renal toxicities of chemotherapy. Semin Oncol 19:521-858
11. Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897-907 (Pubitemid 43785797)
12. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M (2007) International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphospho-nates in elderly patients. Eur J Cancer 43:852-858 (Pubitemid 46366687)
13. Boonen S, Black DM, Colón-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P, Haentjens P, Lyles KW (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58(2):292-299 Epub 2010 Jan 8
14. Santini D, Fratto ME, Vincenzi B et al (2006) Zoledronic acid in the management of metastatic bone disease. Expert Opin Biol Ther 6(12):1333-1348 (Pubitemid 44875687)
15. Clézardin P, Ebetino FH, Fournier PGJ (2005) Bisphosphonates and cancer induced bone disease: beyond their antiresorptive activity. Cancer Res 65:4971-4974 (Pubitemid 40827299)
16. Santini D, Vespasiani Gentilucci U, Vincenzi B et al (2003) The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14:1468-1476 (Pubitemid 37304600)
17. Santini D, Galluzzo S, Vincenzi B et al (2007) New developments of aminobisphosphonates: the double face of Janus. Ann Oncol 18(Suppl 6):vi164-7S
18. Caraglia M, Santini D, Marra M et al (2006) Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13:7-26
19. Daubiné F, Céline Le Gall C, Gasser J, Green J, Clézardin P (2007) Antitumor Effects of Clinical Dosing Regimens of Bisphosphonates in Experimental Breast Cancer Bone Metastasis. JNCI 99(4):322-330 (Pubitemid 47073494)
20. Diel IJ, Solomayer EF, Costa SD et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363 (Pubitemid 28363797)
21. Powles T, McCroskey E, Paterson A (2006) Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin Cancer Res 12:6301s-6304s (Pubitemid 44703807)
22. Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2006) 10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I 24(18 Suppl):Abstr 676
23. Jaschke A, Bastert G, Solomayer EF et al (2004) Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up. J Clin Oncol (Meeting Abstracts) 22:529
24. Ha TC, Li H (2007) Meta-analysis of clodronate and breast cancer survival. Br J Cancer 6: 1796-1801 (Pubitemid 46912011)
25. Eidtmann H, Bundred NJ, DeBoer R et al. (2008) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. 31st Annual Meeting of the San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX (abstr 44)
26. Aapro M (2006) Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZOFAST program. Breast 15(Suppl 1): S30-S40 (Pubitemid 43264339)
27. Gnant M, Mlineritsch B, Schippinger W et al (2009a) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691
28. Eidtmann H, Bundred NJ, DeBoer R et al (2010) The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Ann Oncol 21(11):2188-2194
29. Coleman R et al. (2009) Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at: 32nd SABCS; 2009. Abstract 4082
30. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, ABCSG-12 Trial Investigators, Marth C (2009b) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7):679-691 Erratum in: N Engl J Med. 2009 May 28;360(22):2379
31. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28(22):3582-3590 Epub 2010 Jun 21
32. Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28(22):3577-3581 Epub 2010 Jun 21
33. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H, AZURE (BIG01/04) Investigators (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102(7):1099-1105 Epub 2010 Mar 16
34. Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Davies C, Bell RS4-5 Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer. The AZURE Trial (BIG 01/04). Presented at: SABCS 2010
35. Mauri D, Valachis A, Polyzos NP et al (2010) Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials. J Natl Compr Canc Netw 8:279-286
36. Mason MD, Sydes MR, Glaholm J et al (2007) Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 99(10):765-776 (Pubitemid 47073523)
37. Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88(12 Suppl): 2892-2898 (Pubitemid 30413169)
38. Stopeck A, Lipton A, Body JJ et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized double-blind study. J Clin Oncol 28(35):5132-5139
39. Vadhan-Raj S, Henry DH, von Moos R et al (2010) Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. J Clin Oncol 28(Suppl):15s abstract 9042
40. Fizazi K, Carducci MA, Smith MR et al (2010) A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 28(Suppl):18s abstract LBA4507
41. Cummings SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention offractures in postmenopausal women with osteoporosis. NEngl J Med 361:756-765
42. Ellis GK, Bone HG, Chlebowski R et al (2009) Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 118:81-87
43. National Institutes of Health. A randomised, double-blind, placebo-controlled, multi-centre phase 3 study to determine the treatment effect of denosumab in subjects with non-metastatic breast cancer receiving aromatase inhibitor therapy. Clinicaltrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00556374. Accessed August 6, 2010
44. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HALT Prostate Cancer Study Group (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745-755 Epub 2009 Aug 11